These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1052 related items for PubMed ID: 30405641

  • 1. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
    Narang V, Lu Y, Tan C, Camous XFN, Nyunt SZ, Carre C, Mok EWH, Wong G, Maurer-Stroh S, Abel B, Burdin N, Poidinger M, Tambyah PA, Bosco N, Visan L, Ng TP, Larbi A.
    Front Immunol; 2018; 9():2465. PubMed ID: 30405641
    [Abstract] [Full Text] [Related]

  • 2. Kinetics of the antibody response to seasonal influenza vaccination among the elderly.
    Kositanont U, Assantachai P, Wasi C, Puthavathana P, Praditsuwan R.
    Viral Immunol; 2012 Dec; 25(6):471-6. PubMed ID: 23061793
    [Abstract] [Full Text] [Related]

  • 3. The effect of frailty on HAI response to influenza vaccine among community-dwelling adults ≥ 50 years of age.
    Moehling KK, Nowalk MP, Lin CJ, Bertolet M, Ross TM, Carter CE, Susick M, Saul SG, Kaynar AM, Bromberger JT, Zimmerman RK.
    Hum Vaccin Immunother; 2018 Feb 01; 14(2):361-367. PubMed ID: 29172948
    [Abstract] [Full Text] [Related]

  • 4. Preexisting Immunity, Not Frailty Phenotype, Predicts Influenza Postvaccination Titers among Older Veterans.
    Van Epps P, Tumpey T, Pearce MB, Golding H, Higgins P, Hornick T, Burant C, Wilson BM, Banks R, Gravenstein S, Canaday DH.
    Clin Vaccine Immunol; 2017 Mar 01; 24(3):. PubMed ID: 28100496
    [Abstract] [Full Text] [Related]

  • 5. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.
    Loebermann M, Voss U, Meyer S, Bosse D, Fritzsche C, Klammt S, Frimmel S, Riebold D, Reisinger EC.
    PLoS One; 2013 Mar 01; 8(8):e70866. PubMed ID: 23976960
    [Abstract] [Full Text] [Related]

  • 6. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH.
    Vaccine; 2013 May 01; 31(19):2358-65. PubMed ID: 23499604
    [Abstract] [Full Text] [Related]

  • 7. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M, Dubiel P, Drozd-Dąbrowska M, Hallmann-Szelińska E, Szymański K, Brydak LB.
    Int J Environ Res Public Health; 2019 Nov 14; 16(22):. PubMed ID: 31739554
    [Abstract] [Full Text] [Related]

  • 8. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.
    Vaccine; 2012 Jun 22; 30(30):4543-51. PubMed ID: 22475864
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
    Vinnemeier CD, Fischer-Herr J, Meyer S, Liebig K, Theeß W, Burchard GD, Cramer JP.
    Hum Vaccin Immunother; 2014 Jun 22; 10(2):441-8. PubMed ID: 24240428
    [Abstract] [Full Text] [Related]

  • 10. Neutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination.
    Levine MZ, Martin JM, Gross FL, Jefferson S, Cole KS, Archibald CA, Nowalk MP, Susick M, Moehling K, Spencer S, Chung JR, Flannery B, Zimmerman RK.
    Clin Vaccine Immunol; 2016 Oct 22; 23(10):831-839. PubMed ID: 27558294
    [Abstract] [Full Text] [Related]

  • 11. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
    Roggelin L, Vinnemeier CD, Meyer S, Witte K, Marx L, Theeß W, Burchard GD, Rolling T, Cramer JP.
    Hum Vaccin Immunother; 2015 Oct 22; 11(10):2370-5. PubMed ID: 26114800
    [Abstract] [Full Text] [Related]

  • 12. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group.
    Boonnak K, Dhitavat J, Thantamnu N, Kosoltanapiwat N, Auayporn M, Jiang L, Puthavathana P, Pitisuttithum P.
    Vaccine; 2017 Dec 19; 35(52):7339-7346. PubMed ID: 29157960
    [Abstract] [Full Text] [Related]

  • 13. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 19; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y, Kimachi K, Okada Y, Matsuura K, Ooyama Y, Ibaragi K, Kino Y, Ueda K.
    Microbiol Immunol; 2015 Oct 19; 59(10):597-604. PubMed ID: 26272602
    [Abstract] [Full Text] [Related]

  • 15. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 19; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 16. Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®.
    Shen Y, Hu Y, Meng F, Du W, Li W, Song Y, Ji X, Huo L, Fu Z, Yin W.
    Hum Vaccin Immunother; 2016 May 03; 12(5):1229-34. PubMed ID: 26934750
    [Abstract] [Full Text] [Related]

  • 17. A comparison of viral microneutralization and haemagglutination inhibition assays as measures of seasonal inactivated influenza vaccine immunogenicity in the first year after reduced intensity conditioning, lymphocyte depleted allogeneic haematopoietic stem cell transplant.
    Miller PDE, de Silva TI, Leonard H, Anthias C, Hoschler K, Goddard K, Peggs K, Madrigal A, Snowden JA.
    Vaccine; 2019 Jan 14; 37(3):452-457. PubMed ID: 30554797
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults.
    Stevanovic G, Lavadinovic L, Filipovic Vignjevic S, Holt R, Ilic K, Berlanda Scorza F, Sparrow E, Stoiljkovic V, Torelli G, Madenwald T, Socquet M, Barac A, Ilieva-Borisova Y, Pelemis M, Flores J.
    Hum Vaccin Immunother; 2018 Mar 04; 14(3):579-586. PubMed ID: 29239682
    [Abstract] [Full Text] [Related]

  • 19. A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60-85 years old) and very elderly (>85 years old) institutionalized subjects.
    Nunzi E, Iorio AM, Camilloni B.
    Hum Vaccin Immunother; 2017 Nov 02; 13(11):2659-2668. PubMed ID: 28922621
    [Abstract] [Full Text] [Related]

  • 20. Effects of Banafine® , a fermented green banana-derived acidic glycoconjugate, on influenza vaccine antibody titer in elderly patients receiving gastrostomy tube feeding.
    Horie K, Hossain MS, Kim Y, Akiko I, Kon R, Yamatsu A, Kishima M, Nishikimi T, Kim M.
    J Food Sci; 2021 Apr 02; 86(4):1410-1417. PubMed ID: 33768522
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.